Targeting PI3K/Akt/mTOR cascade: The medicinal potential, updated research highlights and challenges ahead

Current Medicinal Chemistry

Volumn 20, Issue 24, 2013, Pages 2991-3010

  Ma, X ^a   Hu, Y ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cancer treatment; Candidates; Kinase specificity; Multiple inhibitory activities; Pharmacokinetic profiles; PI3K axis inhibitors; PI3K Akt mTOR cascade

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; APITOLISIB; AZD 8055; BEVACIZUMAB; BGT 226; BUPARLISIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEFITINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PKI 402; PKI 587; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 001;

AMINO ACID SEQUENCE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL DIVISION; CELL FUNCTION; CELL GROWTH; CELL MEMBRANE; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMICAL STRUCTURE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); COWDEN SYNDROME; CRYSTAL STRUCTURE; DERIVATIZATION; DIARRHEA; DRUG SAFETY; DRUG TOLERANCE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; FATIGUE; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY LOSS; HUMAN; HYPERGLYCEMIA; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER BLOOD FLOW; LIVER TOXICITY; LYMPHOMA; MAST CELL DEGRANULATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MELANOMA; METASTATIC COLORECTAL CANCER; MICROTUBULE ASSEMBLY; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; MULTIPLE MYELOMA; MYELOMA CELL; NAUSEA; NEGATIVE FEEDBACK; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PLASMA VOLUME; PROSTATE CANCER; PROTEIN TARGETING; RNA TRANSLATION; ROOM TEMPERATURE; SECOND MESSENGER; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VIRUS ONCOGENE; VOMITING;

3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASES; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PRODRUGS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84880265912     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990124     Document Type: Article

References (120)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA: a cancer journal for clinicians, 2009, 59, 225-249.
2. Kamb, A.; Wee, S.; Lengauer, C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov., 2007, 6, 115-120.
3. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2, 489-501.
4. Garcia-Echeverria, C.; Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27, 5511-5526.
5. Wu, P.; Hu, Y.Z. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr. Med. Chem., 2010, 17, 4326-4341.
6. Bowles, D.W.; Jimeno, A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin. Inv. Drugs, 2011, 20, 507-518.
7. Yap, T.A.; Garrett, M.D.; Walton, M.I.; Raynaud, F.; de Bono, J.S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol., 2008, 8, 393-412.
8. Ciraolo, E.; Morello, F.; Hirsch, E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr. Med. Chem., 2011, 18, 2674-2685.
9. Arcaro, A.; Wymann, M.P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J., 1993, 296, 297-301.
10. Vlahos, C.J.; Matter, W.F.; Hui, K.Y.; Brown, R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4- one (LY294002). J. Biol. Chem., 1994, 269, 5241-5248.
11. Wymann, M.P.; Bulgarelli-Leva, G.; Zvelebil, M.J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M.D.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol., 1996, 16, 1722-1733.
12. Wu, P.; Liu, T.; Hu, Y. PI3K inhibitors for cancer therapy: what has been achieved so far? Curr. Med. Chem., 2009, 16, 916-930.
13. Bedogni, B.; O'Neill, M.S.; Welford, S.M.; Bouley, D.M.; Giaccia, A.J.; Denko, N.C.; Powell, M.B. Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogenactivated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res., 2004, 64, 2552-2560.
14. Alcazar, I.; Marques, M.; Kumar, A.; Hirsch, E.; Wymann, M.; Carrera, A.C.; Barber, D.F. Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation. J. Exp. Med., 2007, 204, 2977-2987.
15. Leevers, S.J.; Vanhaesebroeck, B.; Waterfield, M.D. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell Biol., 1999, 11, 219-225.
16. Lawlor, M.A.; Alessi, D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci., 2001, 114, 2903-2910.
17. Vanhaesebroeck, B.; Leevers, S.J.; Ahmadi, K.; Timms, J.; Katso, R.; Driscoll, P.C.; Woscholski, R.; Parker, P.J.; Waterfield, M.D. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem., 2001, 70, 535-602.
18. Cantley, L.C., The phosphoinositide 3-kinase pathway. Science, 2002, 296, 1655-1657.
19. Wendel, H.G.; De Stanchina, E.; Fridman, J.S.; Malina, A.; Ray, S.; Kogan, S.; Cordon-Cardo, C.; Pelletier, J.; Lowe, S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428, 332-337.
20. Omar, B.; Zmuda-Trzebiatowska, E.; Manganiello, V.; Goransson, O.; Degerman, E. Regulation of AMP-Activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell. Signal., 2009, 21, 760-766.
21. Fasolo, A.; Sessa, C. Targeting mTOR pathways in human malignancies. Curr. Pharm. Design, 2012, 18, 2766-2777.
22. Altomare, D.A.; Khaled, A.R. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr. Med. Chem., 2012, 19, 3748-3762.
23. Whitman, M.; Kaplan, D.R.; Schaffhausen, B.; Cantley, L.; Roberts, T.M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature, 1985, 315, 239-242.
24. Vanhaesebroeck, B.; Leevers, S.J.; Panayotou, G.; Waterfield, M.D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci., 1997, 22, 267-272.
25. Sabbah, D.A.; Brattain, M.G.; Zhong, H. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr. Med. Chem., 2011, 18, 5528-5544.
26. Shayesteh, L.; Lu, Y.; Kuo, W.L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G.B.; Gray, J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 1999, 21, 99-102.
27. Ma, Y.Y.; Wei, S.J.; Lin, Y.C.; Lung, J.C.; Chang, T.C.; Whang-Peng, J.; Liu, J.M.; Yang, D.M.; Yang, W.K.; Shen, C.Y. PIK3CA as an oncogene in cervical cancer. Oncogene, 2000, 19, 2739-2744.
28. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304, 554.
29. Campbell, I.G.; Russell, S.E.; Choong, D.Y.; Montgomery, K.G.; Ciavarella, M.L.; Hooi, C.S.; Cristiano, B.E.; Pearson, R.B.; Phillips, W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res., 2004, 64, 7678-7681.
30. Kang, S.; Bader, A.G.; Vogt, P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. P. Natl. Acad. Sci. USA., 2005, 102, 802-807.
31. Parsons, D.W.; Wang, T.L.; Samuels, Y.; Bardelli, A.; Cummins, J.M.; DeLong, L.; Silliman, N.; Ptak, J.; Szabo, S.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Lengauer, C.; Velculescu, V.E. Colorectal cancer: mutations in a signalling pathway. Nature, 2005, 436, 792.
32. Hopkin, K. A surprising function for the PTEN tumor suppressor. Science, 1998, 282, 1027,1029-1030.
33. Maehama, T.; Dixon, J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol., 1999, 9, 125-128.
34. Simpson, L.; Parsons, R. PTEN: life as a tumor suppressor. Exp. Cell Res., 2001, 264, 29-41.
35. Chow, L.M.; Baker, S.J. PTEN function in normal and neoplastic growth. Cancer Lett., 2006, 241, 184-196.
36. Bader, A.G.; Kang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer, 2005, 5, 921-929.
37. Yu, J.; Zhang, Y.; McIlroy, J.; Rordorf-Nikolic, T.; Orr, G.A.; Backer, J.M. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol., 1998, 18, 1379-1387.
38. Fresno Vara, J.A.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; Gonzalez-Baron, M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev., 2004, 30, 193-204.
39. Fasolo, A.; Sessa, C. mTOR inhibitors in the treatment of cancer. Expert Opin. Inv. Drugs, 2008, 17, (11), 1717-1734.
40. Lawlor, M.A.; Mora, A.; Ashby, P.R.; Williams, M.R.; Murray-Tait, V.; Malone, L.; Prescott, A.R.; Lucocq, J.M.; Alessi, D.R. Essential role of PDK1 in regulating cell size and development in mice. EMBO J., 2002, 21, 3728-3738.
41. Pullen, N.; Dennis, P.B.; Andjelkovic, M.; Dufner, A.; Kozma, S.C.; Hemmings, B.A.; Thomas, G. Phosphorylation and activation of p70s6k by PDK1. Science, 1998, 279, 707-710.
42. Mora, A.; Komander, D.; van Aalten, D.M.; Alessi, D.R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol., 2004, 15, 161-170.
43. Jacinto, E.; Lorberg, A. TOR regulation of AGC kinases in yeast and mammals. Biochem. J., 2008, 410, 19-37.
44. Peifer, C.; Alessi, D.R. Small-molecule inhibitors of PDK1. ChemMedChem, 2008, 3, 1810-1838.
45. Bobkova, E.V.; Weber, M.J.; Xu, Z.; Zhang, Y.L.; Jung, J.; Blume-Jensen, P.; Northrup, A.; Kunapuli, P.; Andersen, J.N.; Kariv, I. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J. Biol. Chem., 2010, 285, 18838-18846.
46. Alessi, D.R.; James, S.R.; Downes, C.P.; Holmes, A.B.; Gaffney, P.R.; Reese, C.B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol.: CB, 1997, 7, 261-269.
47. Komander, D.; Fairservice, A.; Deak, M.; Kular, G.S.; Prescott, A.R.; Peter Downes, C.; Safrany, S.T.; Alessi, D.R.; van Aalten, D.M. Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J., 2004, 23, 3918-3928.
48. Ali, I.U.; Schriml, L.M.; Dean, M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer I., 1999, 91, 1922-1932.
49. Lee, J.W.; Soung, Y.H.; Kim, S.Y.; Lee, H.W.; Park, W.S.; Nam, S.W.; Kim, S.H.; Lee, J.Y.; Yoo, N.J.; Lee, S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24, 1477-1480.
50. Saal, L.H.; Holm, K.; Maurer, M.; Memeo, L.; Su, T.; Wang, X.; Yu, J.S.; Malmstrom, P.O.; Mansukhani, M.; Enoksson, J.; Hibshoosh, H.; Borg, A.; Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res., 2005, 65, 2554-2559.
51. Velho, S.; Oliveira, C.; Ferreira, A.; Ferreira, A.C.; Suriano, G.; Schwartz, S., Jr.; Duval, A.; Carneiro, F.; Machado, J.C.; Hamelin, R.; Seruca, R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer, 2005, 41, 1649-1654.
52. Tokunaga, E.; Oki, E.; Egashira, A.; Sadanaga, N.; Morita, M.; Kakeji, Y.; Maehara, Y. Deregulation of the Akt pathway in human cancer. Curr. Cancer Drug Tar., 2008, 8, 27-36.
53. Workman, P.; Clarke, P.A.; Guillard, S.; Raynaud, F.I. Drugging the PI3 kinome. Nat. Biotechnol., 2006, 24, 794-796.
54. Sarker, D.; Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res., 2007, 96, 213-268.
55. Weinstein, I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science, 2002, 297, 63-64.
56. Weinstein, I.B.; Joe, A.K. Mechanisms of disease: Oncogene addiction-A rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol., 2006, 3, 448-457.
57. Cheng, J.Q.; Lindsley, C.W.; Cheng, G.Z.; Yang, H.; Nicosia, S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene, 2005, 24, 7482-7492.
58. Walker, E.H.; Pacold, M.E.; Perisic, O.; Stephens, L.; Hawkins, P.T.; Wymann, M.P.; Williams, R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 2000, 6, 909-919.
59. Raynaud, F.I.; Eccles, S.; Clarke, P.A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L.M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67, 5840-5850.
60. Werzowa, J.; Koehrer, S.; Strommer, S.; Cejka, D.; Fuereder, T.; Zebedin, E.; Wacheck, V. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J. Invest. Dermatol., 2011, 131, 495-503.
61. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F.I.; Workman, P.; Waterfield, M.D.; Parker, P. Synthesis and biological evaluation of pyrido[3',2':4,5] furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2438-2442.
62. Baggiolini, M.; Dewald, B.; Schnyder, J.; Ruch, W.; Cooper, P.H.; Payne, T.G. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp. Cell Res., 1987, 169, 408-418.
63. Ihle, N.T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M.I.; Paine-Murrieta, G.; Minion, D.J.; Halter, R.J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther., 2004, 3, 763-772.
64. Zhu, T.; Gu, J.; Yu, K.; Lucas, J.; Cai, P.; Tsao, R.; Gong, Y.; Li, F.; Chaudhary, I.; Desai, P.; Ruppen, M.; Fawzi, M.; Gibbons, J.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Zask, A. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. J. Med. Chem., 2006, 49, 1373-1378.
65. Norman, B.H.; Shih, C.; Toth, J.E.; Ray, J.E.; Dodge, J.A.; Johnson, D.W.; Rutherford, P.G.; Schultz, R.M.; Worzalla, J.F.; Vlahos, C.J. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J. Med. Chem., 1996, 39, 1106-1111.
66. Yu, K.; Lucas, J.; Zhu, T.; Zask, A.; Gaydos, C.; Toral-Barza, L.; Gu, J.; Li, F.; Chaudhary, I.; Cai, P.; Lotvin, J.; Petersen, R.; Ruppen, M.; Fawzi, M.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Frost, P.; Gibbons, J. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol. Ther., 2005, 4, 538-545.
67. Garlich, J.R.; De, P.; Dey, N.; Su, J.D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G.B.; Kundra, V.; Shu, H.K.; Peng, Q.; Durden, D.L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res., 2008, 68, 206-215.
68. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updates, 2008, 11, 32-50.
69. Mita, M.; Sankhala, K.; Abdel-Karim, I.; Mita, A.; Giles, F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin. Inv. Drugs, 2008, 17, (12), 1947-1954.
70. Hartford, C.M.; Desai, A.A.; Janisch, L.; Karrison, T.; Rivera, V.M.; Berk, L.; Loewy, J.W.; Kindler, H.; Stadler, W.M.; Knowles, H.L.; Bedrosian, C.; Ratain, M.J. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res., 2009, 15, 1428-1434.
71. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem., 2006, 14, 6847-6858.
72. Folkes, A.J.; Ahmadi, K.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Depledge, P.; Eccles, S.A.; Friedman, L.S.; Hayes, A.; Hancox, T.C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A.G.; Pang, J.; Patel, S.; Pergl-Wilson, G.H.; Raynaud, F.I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M.H.; Valenti, M.; Wallweber, H.J.; Wan, N.C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M.J.; Shuttleworth, S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51, 5522-5532.
73. Raynaud, F.I.; Eccles, S.A.; Patel, S.; Alix, S.; Box, G.; Chuckowree, I.; Folkes, A.; Gowan, S.; De Haven Brandon, A.; Di Stefano, F.; Hayes, A.; Henley, A.T.; Lensun, L.; Pergl-Wilson, G.; Robson, A.; Saghir, N.; Zhyvoloup, A.; McDonald, E.; Sheldrake, P.; Shuttleworth, S.; Valenti, M.; Wan, N.C.; Clarke, P.A.; Workman, P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther., 2009, 8, 1725-1738.
74. Venkatesan, A.M.; Dehnhardt, C.M.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R.T.; Chaudhary, I.; Mansour, T.S. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem., 2010, 53, 2636-2645.
75. Jackson, S.P.; Schoenwaelder, S.M.; Goncalves, I.; Nesbitt, W.S.; Yap, C.L.; Wright, C.E.; Kenche, V.; Anderson, K.E.; Dopheide, S.M.; Yuan, Y.; Sturgeon, S.A.; Prabaharan, H.; Thompson, P.E.; Smith, G.D.; Shepherd, P.R.; Daniele, N.; Kulkarni, S.; Abbott, B.; Saylik, D.; Jones, C.; Lu, L.; Giuliano, S.; Hughan, S.C.; Angus, J.A.; Robertson, A.D.; Salem, H.H. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat. Med., 2005, 11, 507-514.
76. Garcia, A.; Kim, S.; Bhavaraju, K.; Schoenwaelder, S.M.; Kunapuli, S.P. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem. J, 2010, 429, 369-377.
77. Ruckle, T.; Schwarz, M.K.; Rommel, C. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug discov., 2006, 5, 903-918.
78. Knobbe, C.B.; Trampe-Kieslich, A.; Reifenberger, G. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropath. Appl. Neuro., 2005, 31, 486-490.
79. Billottet, C.; Grandage, V.L.; Gale, R.E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene, 2006, 25, 6648-6659.
80. Matthew, T. B.; Sabina, P.; Allan, W.; Zhi-Jie, N.; Mark, K.; Thomas, H.; Gordana, A.; Keith, P.; Yanchen, Z.; Sarah, B.; Kelly, F.; Simon, N.; Aaron, S.; Joelle, V.; Joshua, H.; Kay, H.; Ed, I.; Xiaohua, X.; Daniel, M.; Hanne, M.; Isabelle, L.; Marion, W.; Susan, K.; Kenneth, C.; Michael, C.; Dirksen, B.; Kevin, S.; Isabel, Z.; Sauveur-Michel, M.; Charles, F. V. Identification of NVPBKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med. Chem. Lett., 2011, 2, 774-779.
81. Yaguchi, S.; Fukui, Y.; Koshimizu, I.; Yoshimi, H.; Matsuno, T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer I., 2006, 98, 545-556.
82. Bendell, J.C.; Rodon, J.; Burris, H.A.; de Jonge, M.; Verweij, J.; Birle, D.; Demanse, D.; De Buck, S.S.; Ru, Q.C.; Peters, M.; Goldbrunner, M.; Baselga, J. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol., 2012, 30, 282-290.
83. Hayakawa, M.; Kaizawa, H.; Kawaguchi, K.; Ishikawa, N.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F.I.; Waterfield, M.D.; Parker, P.; Workman, P. Synthesis and biological evaluation of imidazo[1,2-A]pyridine de rivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem., 2007, 15, 403-412.
84. Hayakawa, M.; Kawaguchi, K.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F.I.; Parker, P.; Workman, P.; Waterfield, M.D. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-A]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem., 2007, 15, 5837-5844
85. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098-1101.
86. O'Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66, 1500-1508.
87. Wang, X.; Yue, P.; Chan, C.B.; Ye, K.; Ueda, T.; Watanabe-Fukunaga, R.; Fukunaga, R.; Fu, H.; Khuri, F.R.; Sun, S.Y. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol. Cell. Biol., 2007, 27, 7405-7413.
88. Zask, A.; Kaplan, J.; Verheijen, J.C.; Richard, D.J.; Curran, K.; Brooijmans, N.; Bennett, E.M.; Toral-Barza, L.; Hollander, I.; Ayral-Kaloustian, S.; Yu, K. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J. Med. Chem., 2009, 52, 7942-7945.
89. Chresta, C.M.; Davies, B.R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S.E.; Vincent, J.P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G.C.; Guichard, S.; Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res., 2010, 70, 288-298.
90. Carayol, N.; Vakana, E.; Sassano, A.; Kaur, S.; Goussetis, D.J.; Glaser, H.; Druker, B.J.; Donato, N.J.; Altman, J.K.; Barr, S.; Platanias, L.C. Critical roles for mTORC2-And rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABLexpressing leukemic cells. P. Natl. Acad. Sci. USA., 2010, 107, 12469-12474.
91. Tsou, H.R.; MacEwan, G.; Birnberg, G.; Grosu, G.; Bursavich, M.G.; Bard, J.; Brooijmans, N.; Toral-Barza, L.; Hollander, I.; Mansour, T.S.; Ayral-Kaloustian, S.; Yu, K. Discovery and optimization of 2-(4-substituted- pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-o nes as potent and selective ATPcompetitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett., 2010, 20, 2321-2325.
92. Watanabe, R.; Wei, L.; Huang, J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J. Nucl. Med., 2011, 52, 497-500.
93. Garcia-Echeverria, C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. Med. Chem. Lett., 2010, 20, 4308-4312.
94. Mattmann, M.E.; Stoops, S.L.; Lindsley, C.W. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin. Ther. Pat., 2011, 21, 1309-1338.
95. Pal, S.K.; Reckamp, K.; Yu, H.; Figlin, R.A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Inv. Drugs, 2010, 19, 1355-1366.
96. Gills, J.J.; Dennis, P.A. Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep., 2009, 11, 102-110.
97. Hideshima, T.; Catley, L.; Yasui, H.; Ishitsuka, K.; Raje, N.; Mitsiades, C.; Podar, K.; Munshi, N.C.; Chauhan, D.; Richardson, P.G.; Anderson, K.C. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107, 4053-4062.
98. Vink, S.R.; Schellens, J.H.; Beijnen, J.H.; Sindermann, H.; Engel, J.; Dubbelman, R.; Moppi, G.; Hillebrand, M.J.; Bartelink, H.; Verheij, M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother. Oncol., 2006, 80, 207-213.
99. Moses, S.A.; Ali, M.A.; Zuohe, S.; Du-Cuny, L.; Zhou, L.L.; Lemos, R.; Ihle, N.; Skillman, A.G.; Zhang, S.; Mash, E.A.; Powis, G.; Meuillet, E.J. In vitro and in vivo activity of novel smallmolecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res., 2009, 69, 5073-5081.
100. Meuillet, E.J.; Zuohe, S.; Lemos, R.; Ihle, N.; Kingston, J.; Watkins, R.; Moses, S.A.; Zhang, S.; Du-Cuny, L.; Herbst, R.; Jacoby, J.J.; Zhou, L.L.; Ahad, A.M.; Mash, E.A.; Kirkpatrick, D.L.; Powis, G. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol. Cancer Ther., 2010, 9, 706-717.
101. Ahad, A.M.; Zuohe, S.; Du-Cuny, L.; Moses, S.A.; Zhou, L.L.; Zhang, S.; Powis, G.; Meuillet, E.J.; Mash, E.A. Development of sulfonamide AKT PH domain inhibitors. Bioorg. Med. Chem., 2011, 19, 2046-2054.
102. Heerding, D.A.; Rhodes, N.; Leber, J.D.; Clark, T.J.; Keenan, R.M.; Lafrance, L.V.; Li, M.; Safonov, I.G.; Takata, D.T.; Venslavsky, J.W.; Yamashita, D.S.; Choudhry, A.E.; Copeland, R.A.; Lai, Z.; Schaber, M.D.; Tummino, P.J.; Strum, S.L.; Wood, E.R.; Duckett, D.R.; Eberwein, D.; Knick, V.B.; Lansing, T.J.; McConnell, R.T.; Zhang, S.; Minthorn, E.A.; Concha, N.O.; Warren, G.L.; Kumar, R. Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1- ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyri din-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J. Med. Chem., 2008, 51, 5663-5679.
103. Wang, P.; Zhang, L.; Hao, Q.; Zhao, G. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB. Mini Rev. Med. Chem., 2011, 11, 1093-1107.
104. Lindsley, C.W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr. Top. Med. Chem., 2010, 10, 458-477.
105. Falasca, M.; Chiozzotto, D.; Godage, H.Y.; Mazzoletti, M.; Riley, A.M.; Previdi, S.; Potter, B.V.; Broggini, M.; Maffucci, T., A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Brit. J. Cancer, 2010, 102, 104-114.
106. Weigelt, B.; Warne, P.H.; Downward, J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene, 2011, 30, 3222-3233.
107. Mazzoletti, M.; Bortolin, F.; Brunelli, L.; Pastorelli, R.; Di Giandomenico, S.; Erba, E.; Ubezio, P.; Broggini, M. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res., 2011, 71, 4573-4584.
108. Markman, B.; Atzori, F.; Perez-Garcia, J.; Tabernero, J.; Baselga, J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann. Oncol., 2010, 21, 683-691.
109. Stauffer, F.; Maira, S.M.; Furet, P.; Garcia-Echeverria, C. Imidazo[ 4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett., 2008, 18, 1027-1030.
110. Maira, S.M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther., 2008, 7, 1851-1863.
111. Baumann, P.; Schneider, L.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anti-cancer Drugs, 2012, 23, 131-138.
112. Chang, K.Y.; Tsai, S.Y.; Wu, C.M.; Yen, C.J.; Chuang, B.F.; Chang, J.Y. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin. Cancer Res., 2011, 17, 7116-7126.
113. Corona, P.; Carta, A.; Loriga, M.; Vitale, G.; Paglietti, G. Synthesis and in vitro antitumor activity of new quinoxaline derivatives. Eur. J. Med. Chem., 2009, 44, 1579-1591.
114. Steven, D. K.; Nicholas, D. A.; Joelle, L. B.; Amita, M. C.; Michael, G. D.; Carla, A. D.; Juan, I. L.; Ken, A. N.; Cynthia, A. P.; Lance, H. R.; Martha, A. S.; Stanley, J. S.; Glenn, S. V. A.; Jeffrey, D. C.; Melody A. D.; Patricia, A. El.; Christine, M. G.; Eric, G.; Seth, A. G.; Richard, R. G.; Jeffrey, R. J.; Kevin, L. K.; Lusong, L.; Kaushik, R.; Christian, S. S.; Chiu-Mei, S.; David, S.; Peter, J. T.; Ronald, J. W.; Kurt, R. A.; Dashyant, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett., 2010, 1, 39-43.
115. D'Angelo, N.D.; Kim, T.S.; Andrews, K.; Booker, S.K.; Caenepeel, S.; Chen, K.; D'Amico, D.; Freeman, D.; Jiang, J.; Liu, L.; McCarter, J.D.; San Miguel, T.; Mullady, E.L.; Schrag, M.; Subramanian, R.; Tang, J.; Wahl, R.C.; Wang, L.; Whittington, D.A.; Wu, T.; Xi, N.; Xu, Y.; Yakowec, P.; Yang, K.; Zalameda, L.P.; Zhang, N.; Hughes, P.; Norman, M.H. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. J. Med. Chem., 2011, 54, 1789-1811.
116. Nishimura, N.; Siegmund, A.; Liu, L.; Yang, K.; Bryan, M.C.; Andrews, K.L.; Bo, Y.; Booker, S.K.; Caenepeel, S.; Freeman, D.; Liao, H.; McCarter, J.; Mullady, E.L.; San Miguel, T.; Subramanian, R.; Tamayo, N.; Wang, L.; Whittington, D.A.; Zalameda, L.; Zhang, N.; Hughes, P.E.; Norman, M.H. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-Activity relationships of a series of quinoline and quinoxaline derivatives. J. Med. Chem., 2011, 54, 4735-4751.
117. Sutherlin, D.P.; Bao, L.; Berry, M.; Castanedo, G.; Chuckowree, I.; Dotson, J.; Folks, A.; Friedman, L.; Goldsmith, R.; Gunzner, J.; Heffron, T.; Lesnick, J.; Lewis, C.; Mathieu, S.; Murray, J.; Nonomiya, J.; Pang, J.; Pegg, N.; Prior, W.W.; Rouge, L.; Salphati, L.; Sampath, D.; Tian, Q.; Tsui, V.; Wan, N.C.; Wang, S.; Wei, B.; Wiesmann, C.; Wu, P.; Zhu, B.Y.; Olivero, A. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J. Med. Chem., 2011, 54, 7579-7587.
118. Hengmiao, C.; Shubha, B.; Simon, B.; Martin, E.; Jacqui, H.; Qiyue, H.; Robert, K.; Daniel, R. K.; Matthew, A. M.; Sacha, N.; Shaoxian, S.; Eric, Z. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. Med. Chem. Commun., 2010, 1, 139-144.
119. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69, 89-95.
120. Zhang, J.; Grindley, J.C.; Yin, T.; Jayasinghe, S.; He, X.C.; Ross, J.T.; Haug, J.S.; Rupp, D.; Porter-Westpfahl, K.S.; Wiedemann, L.M.; Wu, H.; Li, L. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature, 2006, 441, 518-522.